To Ocugen CEO Shankar Musunuri, Ph.D., most gene therapy biotechs today lack vision. | Many gene therapy outfits focus on ...
The Breakthrough Prize Foundation awarded researchers involved in developing gene therapies for blindness and sickle cell ...
Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...
J&J will hand over the rights to bota-vec for $25 million upfront, clearing MeiraGTx to seek regulatory approvals in the U.S.
Shares of MeiraGTx Holdings (MGTX) slumped on Thursday after the company priced an equity offering in a bid to raise nearly $100M to market a gene therapy known as bota-vec, which it has agreed to ...
Pfizer announced in February 2025 that it was taking Beqvez (fidanacogene elaparvovec), its gene therapy for hemophilia B, ...
After its bet on a rare eye disease gene therapy ended in a phase 3 fail last year, Johnson & Johnson is now returning the ...
Pfizer and BioMarin have pulled their hemophilia gene therapies, citing low demand. To prepare for his presentation at the ...
Sarepta Therapeutics Inc.'s bid for the full Federal Circuit’s review of a revived gene-therapy patent dispute with RegenxBio ...
A new gene therapy for deafness is helping patients hear within weeks, offering hope for children and adults with genetic ...
The global gene therapy market size is projected to expand significantly, with an estimated value of USD 19.3 billion by 2034 ...
From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results